Ingredient Dossier · Xynaptic Drops™ · nutropx.com/science

Liposomal Citicoline

Cognizin® Citicoline in a Lipid-Bilayer Delivery System — A Dietary Supplement for Mental Energy, Focus & Attention

Citicoline (CDP-choline) is a naturally occurring compound the body uses to make phosphatidylcholine, the major structural phospholipid of brain cell membranes, and to support acetylcholine, the neurotransmitter central to attention and memory. Xynaptic Drops™ delivers Cognizin® — Kyowa Hakko Bio’s patented, branded form of citicoline used in the published clinical research — carried within a liposomal lipid bilayer built from sunflower lecithin. 250 mg of Cognizin® per 1 mL liquid serving.

Liposomal delivery 250 mg Cognizin® per 1 mL Vegetarian · Gluten Free · Soy Free Self-affirmed GRAS (2009) Branded: Kyowa Hakko Bio

Cognizin®by Kyowa Hakko Bio

Patented citicoline (2004) Liposomal delivery Sunflower lecithin lipid bilayer Self-affirmed GRAS (2009) EFSA Novel Food (2014)

Xynaptic Drops™ serving

250 mg

Per 1 mL · 500 mg at 2 mL cumulative

Bottle

60 mL

60 servings · 2 fl oz

Delivery format

Liposomal

Sunflower lecithin lipid bilayer

Self-affirmed GRAS

2009

Up to 250 mg/serving

What is it?

Citicoline (cytidine 5′-diphosphocholine, or CDP-choline) is a naturally occurring compound found in every cell of the human body. It is also an obligatory intermediate in the synthesis of phosphatidylcholine — the major structural phospholipid of brain cell membranes — via the Kennedy pathway, first characterized by Eugene Kennedy in 1956.

Orally consumed citicoline is hydrolyzed in the gut to choline and cytidine, both of which are absorbed into circulation and cross the blood–brain barrier. In the brain, these precursors are re-formed into citicoline and feed two biochemically distinct pathways: choline supports the synthesis of acetylcholine (the neurotransmitter most associated with attention and memory), and cytidine (converted to uridine in humans) supports synaptic membrane formation. This dual-pathway biochemistry is the mechanistic basis for citicoline’s investigation in cognitive research.

Cognizin® is Kyowa Hakko Bio’s patented, branded form of citicoline, trademarked in 2004 and the form used in the published clinical research cited on this page. Xynaptic Drops™ delivers 250 mg of Cognizin® per 1 mL liquid serving. The 250 mg serving size matches the dose used in the published McGlade 2012 attention trial in healthy women.

What makes Xynaptic Drops™ distinctive is the liposomal delivery system. The Cognizin® in Xynaptic Drops™ is encapsulated within a lipid bilayer constructed from sunflower lecithin — the same class of phospholipid (phosphatidylcholine) that the citicoline itself is used to build inside the body. Liposomes are microscopic spherical structures that mimic the natural lipid environment of cell membranes, providing an alternative delivery route to standard capsule or tablet formats. The format is especially useful for those who do not tolerate or prefer not to swallow capsules.

Cognizin® vs. generic citicoline: The clinical research cited on this page used Cognizin® specifically (a branded, standardized form of citicoline manufactured by Kyowa Hakko Bio). Generic citicoline products may differ in purity, stability, and manufacturing standards. Xynaptic Drops™ uses Cognizin® specifically — the form for which the published research applies. Note on the liposomal format: citicoline itself is well-absorbed orally (Wurtman 2000), and no published head-to-head trial has directly compared liposomal Cognizin® against capsule Cognizin® in healthy adults. The liposomal format is offered as a delivery alternative with established lipid-vesicle technology, not as a claim of superior bioavailability over the capsule format.

Research timeline

1956

Kennedy pathway identified — Eugene Kennedy characterizes the biochemical pathway by which CDP-choline is incorporated into phosphatidylcholine — establishing citicoline’s structural role in cell membrane synthesis. This is foundational biochemistry, not a cognitive claim.

2000

Wurtman et al. (Biochem Pharmacol) — Human pharmacokinetic study confirms oral CDP-choline produces dose-related, sustained increases in plasma choline and uridine — demonstrating that ingested citicoline delivers bioavailable precursors used by the brain to build phosphatidylcholine and acetylcholine. Notably, in humans the circulating substrates are uridine and choline (not cytidine and choline as in rats).

2002

Babb et al. (Psychopharmacology) — Cognizin® MRS study — First Cognizin-specific in-vivo brain imaging study using 4-Tesla phosphorus magnetic resonance spectroscopy in healthy adults over 50. After 6 weeks of 500 mg/day Cognizin®, brain phosphodiesters increased by 7.3% (P=0.008), indicating measurable changes in phospholipid metabolism.

2004

Cognizin® trademark established — Kyowa Hakko Bio registers the Cognizin® brand for its patented citicoline form.

2008

Silveri et al. (NMR Biomed) — the brain bioenergetics study — 4-Tesla phosphorus MRS in 16 healthy adults at 500 or 2000 mg/day for 6 weeks. Researchers reported significant changes in frontal-lobe phosphocreatine, ATP-related compounds, and membrane phospholipid biomarkers. The source of the widely circulated “14% brain energy” figure — which applies to the 500/2000 mg doses in this n=16 open-label study, not to the 250 mg serving.

2009

Cognizin® self-affirmed GRAS — Cognizin® receives self-affirmed Generally Recognized as Safe status (reviewed by an independent expert panel) for use as a food ingredient at up to 250 mg per serving — matching Xynaptic Drops™’s serving size.

2012

McGlade et al. (Food Nutr Sci) — the dose-matched attention study — Randomized, double-blind, placebo-controlled trial in 60 healthy women aged 40–60 at 250 mg or 500 mg/day Cognizin® for 28 days. Researchers reported associations with attentional performance measures at both doses, with the 250 mg dose matching Xynaptic Drops™’s serving size exactly.

2014

EFSA Novel Food authorization — Following a 2013 positive scientific opinion, the European Commission authorizes Kyowa Hakko’s citicoline as a Novel Food (Commission Implementing Decision 2014/423/EU), at up to 500 mg/day in supplements.

2021

Nakazaki et al. (Journal of Nutrition) — the memory study — Randomized, double-blind, placebo-controlled trial in 100 healthy older adults aged 50–85 with age-associated memory impairment, at 500 mg/day Cognizin® for 12 weeks. Researchers reported associations with episodic memory and composite memory measures vs placebo.

How it works — mechanisms of action

Citicoline’s biochemistry is among the most thoroughly characterized of any cognitive ingredient. Unlike compounds with speculative or preclinical-only mechanisms, citicoline’s role in phosphatidylcholine synthesis (Kennedy pathway) and as a precursor source for acetylcholine and synaptic membranes is established at the textbook biochemistry level.

Professor 5-Brain explains

Citicoline’s job is genuinely simple to describe. It’s a raw materials supplier for two things your brain constantly needs: the lipid building blocks of your neuronal cell membranes (phosphatidylcholine), and the precursor for acetylcholine (your memory and attention neurotransmitter). What makes Cognizin® the well-researched form is the manufacturing consistency — it’s the version used in the clinical trials, and the Babb 2002 and Silveri 2008 brain-imaging studies actually measured the corresponding biomarker changes in healthy adults’ brains after weeks of supplementation. There’s a nice symmetry to the liposomal liquid format too: the citicoline gets carried inside a tiny sphere made from sunflower lecithin — the same class of phospholipid (phosphatidylcholine) that the citicoline itself is used to build once it gets into your cells.

Phosphatidylcholine synthesis (Kennedy pathway)

Citicoline is the obligatory intermediate in phosphatidylcholine synthesis via the Kennedy pathway. Phosphatidylcholine is the major structural phospholipid of brain cell membranes. Babb 2002 directly measured increased phospholipid metabolism biomarkers in healthy adults after 6 weeks of Cognizin®.

Well-established biochemistry · Direct human biomarker evidence

Acetylcholine precursor support

Choline released from citicoline hydrolysis crosses the blood–brain barrier and serves as a precursor for acetylcholine synthesis via choline acetyltransferase. Acetylcholine is the neurotransmitter most directly associated with memory and attention signaling.

Established neurobiochemistry

Brain bioenergetics (ATP-related)

Silveri 2008 used 4-Tesla phosphorus MRS to measure frontal-lobe metabolic biomarkers in healthy adults after 6 weeks of Cognizin®. Researchers reported associations with phosphocreatine, ATP-related compounds, and the phosphocreatine-to-inorganic phosphate ratio. Open-label design (no placebo arm), n=16, used 500 or 2000 mg/day — not the 250 mg Xynaptic serving.

Cognizin-specific brain imaging · Higher doses than Xynaptic serving

Synaptic membrane formation (uridine pathway)

Cytidine released from citicoline is converted to uridine in humans (Wurtman 2000). Uridine participates in synaptic membrane formation through its role in pyrimidine metabolism and phospholipid synthesis. The bioavailability of these precursors is what makes citicoline supplementation mechanistically distinct from supplementing with choline alone.

Established pharmacokinetic mechanism

Blood–brain barrier crossing

Choline and uridine, the precursors released from citicoline in circulation, both cross the blood–brain barrier efficiently. Once in brain tissue, the enzyme CTP:phosphocholine cytidylyltransferase reforms citicoline for the Kennedy pathway. The bioavailability of these precursors at the brain compartment is the mechanistic basis for citicoline’s neuronal effects.

Established pharmacology

Membrane protection mechanisms

Mechanism review work (Adibhatla, Hatcher & Dempsey 2002) characterizes citicoline’s role in attenuating phospholipase A2 activity, restoring phosphatidylcholine, supporting glutathione, and maintaining Na+/K+-ATPase function. These are mechanism-level findings from review and animal research, supporting the broader membrane-health narrative.

Review & animal mechanism research

Liposomal delivery system

The Cognizin® in Xynaptic Drops™ is encapsulated within liposomes — microscopic spherical lipid bilayers formed from sunflower lecithin. Liposomal delivery is an established lipid-vesicle technology that mimics the natural lipid environment of cell membranes. Honest framing: citicoline is already well-absorbed orally per Wurtman 2000; the liposomal format is offered as a delivery alternative for those who prefer liquids or do not tolerate capsules, rather than as a claim of superior bioavailability over capsule Cognizin®.

Established lipid-vesicle technology · No head-to-head Cognizin® comparison published

Who Xynaptic Drops™ is for

Xynaptic Drops™ is designed as a liposomal liquid Cognizin® format, distinct from the multi-ingredient 5-Brain® capsule formula. The design serves four distinct use cases:

Liposomal liquid format

Cognizin® carried within a sunflower-lecithin lipid bilayer. Particularly useful for those who do not tolerate capsules, have difficulty swallowing pills, or have compromised gut function.

Dose flexibility

1 mL delivers 250 mg (matching the McGlade 2012 attention trial dose); 2 mL delivers 500 mg cumulative (matching Nakazaki 2021 memory trial and Silveri 2008 imaging studies). The liquid drops format allows individualized dose calibration.

Stack with 5-Brain®

Can be taken alongside 5-Brain® to layer additional citicoline support onto the multi-ingredient formula. Mechanistically complementary — citicoline addresses phosphatidylcholine synthesis, while 5-Brain® covers six different mechanisms.

Acute or daily use

McGlade 2012 reported associations within 28 days at the 250 mg serving; Babb 2002 measured biomarker changes at 6 weeks; Nakazaki 2021 used 12 weeks. Effects accumulate with consistent daily use.

Human clinical evidence

All studies below used Cognizin® specifically — the same branded citicoline form in Xynaptic Drops™ — with one exception (Wurtman 2000, used generic CDP-choline to establish human pharmacokinetics). Dose context is clearly identified for each study because not all trials used the 250 mg serving size.

Dose-matched to Xynaptic servingRCT · Cognizin-specific

McGlade et al. (2012) — Food and Nutrition Sciences

n=60 healthy women aged 40–60 · Cognizin® 250 mg/day or 500 mg/day vs placebo · 28 days

The published Cognizin® trial closest in dose to Xynaptic Drops™. Researchers reported on the Continuous Performance Test II: the 250 mg group made statistically significantly fewer omission errors (p=0.04) and commission errors (p=0.03) vs placebo. The 500 mg group made significantly fewer commission errors (p=0.03) and trended toward fewer omission errors (p=0.07). Population: middle-aged women specifically; cannot be generalized firmly to men without further study.

DOI 10.4236/fns.2012.36103 Cognizin® 250 mg matches Xynaptic Drops™ serving · Journal not PubMed-indexed

Key takeawayThe dose-matched anchor study. McGlade 2012 used 250 mg Cognizin® — exactly the Xynaptic Drops™ serving size — in healthy adult women, with reported attention measure associations. Limitation: not PubMed-indexed (lower-tier journal); women only.

12-week RCT · Cognizin-specific

Nakazaki et al. (2021) — Journal of Nutrition

n=100 healthy adults 50–85 with age-associated memory impairment (AAMI) · Cognizin® 500 mg/day vs placebo · 12 weeks

Researchers reported statistically significant associations with episodic memory (Paired Associate test: mean change 0.15 vs 0.06 for placebo, P=0.0025) and composite memory (mean 3.78 vs 0.72, P=0.0052). No serious adverse events. Used 500 mg/day — double the Xynaptic Drops™ 1 mL serving (achievable at 2 mL). Population was 50–85 with age-associated memory changes; not generalizable to younger adults. Per EFSA 2024 evaluation, this study did not demonstrate effects on short-term or working memory.

PMID 33978188 Cognizin® 500 mg = Xynaptic Drops™ 2 mL cumulative serving

Key takeawayNakazaki 2021 used 500 mg/day (Xynaptic™ at 2 mL cumulative) in healthy adults 50–85 with age-associated memory changes. Reported associations with episodic and composite memory. EFSA noted no effect on short-term or working memory specifically.

MRS imaging study · Cognizin-specific

Babb et al. (2002) — Psychopharmacology

Healthy adults over 50 · Cognizin® 500 mg/day · Two-phase design (open-label 6 weeks + randomized 6 weeks) · 4-Tesla phosphorus MRS

First Cognizin-specific in-vivo brain imaging study in healthy older adults. After 6 weeks of 500 mg/day, researchers reported brain phosphodiesters increased by 7.3% (P=0.008), including an 11.6% increase in glycerophosphoethanolamine (P=0.002). Phosphodiesters are biomarkers of membrane phospholipid turnover. Direct measurement of phospholipid metabolism change in human brain tissue at the mechanism level.

PMID 12021827 Used 500 mg/day · Brain biomarker measurement only

Key takeawayBabb 2002 directly measured brain phospholipid metabolism biomarkers using 4T MRS imaging after 6 weeks of 500 mg/day Cognizin®. Reported 7.3% increase in phosphodiesters — direct biological evidence at the brain compartment level.

Higher dose than Xynaptic servingMRS imaging · Cognizin-specific

Silveri et al. (2008) — NMR in Biomedicine

n=16 healthy adults (mean age 47.3) · Cognizin® 500 or 2000 mg/day · 6 weeks · 4-Tesla phosphorus MRS · Open-label (no placebo)

The source study for the widely circulated “14% brain energy” figure. Researchers reported significant increases in frontal-lobe phosphocreatine (+7%), beta-nucleoside triphosphates including ATP (+14%), the phosphocreatine-to-inorganic phosphate ratio (+32%), and significant changes in membrane phospholipids. Important caveats: open-label design with no placebo arm, small sample (n=16), used 500 or 2000 mg/day (not the 250 mg Xynaptic serving), and effects tended to be larger in the lower-dose 500 mg group. No cognitive performance testing was performed.

PMID 18816480 Open-label · n=16 · 500–2000 mg (2–8× Xynaptic serving)

Key takeawaySilveri 2008 is the source of the “14% brain energy” marketing figure. Real measurement in 16 healthy adults at 500–2,000 mg/day — but open-label with no placebo arm. We disclose the dose and design context, and do not transfer the quantitative figure to the 250 mg Xynaptic™ serving.

Adolescent males onlyRCT · Cognizin-specific

McGlade et al. (2019) — Journal of Attention Disorders

n=75 healthy adolescent males aged 13–18 · Cognizin® 250 or 500 mg/day vs placebo · 28 days

Researchers reported associations with attention (p=0.02) and psychomotor speed (p=0.03) vs placebo. Higher weight-adjusted dose predicted greater accuracy (p=0.01), better signal detectability (p=0.03), and decreased impulsivity (p=0.01). Population: adolescent males only. Supporting evidence for the citicoline mechanism in healthy people; cannot serve as primary evidence for adult or female populations.

PMID 26179181 Adolescent males · Supporting evidence only

Key takeawayMcGlade 2019 supporting evidence in adolescent males at 250–500 mg Cognizin®. Reported attention and psychomotor speed associations. Population is adolescent males only — cannot serve as primary evidence for adult or female populations.

Pharmacokinetic study

Wurtman et al. (2000) — Biochemical Pharmacology

n=12 fasting subjects · Single oral doses CDP-choline 500, 2000, or 4000 mg vs placebo · Acute · Plasma sampled 1–12 hr

Established the human bioavailability basis for citicoline supplementation. Researchers reported that oral CDP-choline produces dose-related, sustained increases in plasma choline and uridine — confirming that ingested citicoline delivers bioavailable precursors used to build phosphatidylcholine and acetylcholine. Used generic CDP-choline (not Cognizin® specifically); establishes the mechanism applicable to all citicoline forms. Not a cognition study.

PMID 10974208 Generic CDP-choline · Mechanism of bioavailability

Key takeawayWurtman 2000 established the human pharmacokinetic basis for citicoline. Used generic CDP-choline (not Cognizin® specifically) to confirm bioavailability of choline and uridine precursors. Mechanism foundation for all subsequent citicoline research.

Narrative review

Świątkiewicz & Grieb (2023) — Aging and Disease

Narrative review of RCTs and MRS studies in cognitively normal middle-aged and elderly humans

Comprehensive review concluding that in randomized placebo-controlled trials of cognitively normal middle-aged and elderly people, citicoline showed associations with memory measures; MRS studies showed citicoline supports brain choline uptake in older persons. Explains the choline → acetylcholine and cytidine → uridine → phosphatidylcholine pathways clearly. Includes Cognizin-specific trials (Nakazaki 2021, Babb 2002) and broader citicoline literature.

PMID 37196134 Review · Secondary supporting context

Key takeawayŚwiątkiewicz & Grieb 2023 narrative review concluded that in cognitively normal middle-aged and elderly adults, citicoline trials showed positive associations with memory measures. Strong secondary citation; not primary data.

Conference abstract only — not peer-reviewed

Nakazaki et al. (2025) — Conference Presentation

n=148 healthy adults 35–75 with poor sustained attention (127 per-protocol) · Cognizin® 500 mg/day vs placebo · 12 weeks · ClinicalTrials.gov NCT04967157

This finding has only been presented at a scientific symposium and is not yet peer-reviewed or published. Sponsor-reported per-protocol results describe statistically significant differences vs placebo on sustained attention reaction time, rapid visual information processing reaction time, and a mental-energy-related composite. No quantitative effect sizes or p-values are publicly available. We disclose it here for completeness but do not cite it as published evidence. Will be updated when peer-reviewed publication appears.

No PMID · No DOI · Symposium presentation only Sponsor: Kirin Holdings · 5th Symposium on Nutrition for the Ageing Brain (June 2025)

Key takeawayDisclosed for transparency, not cited as evidence. A conference presentation is not peer-reviewed publication — we explicitly do not claim Cognizin® “improves attention” based on unpublished sponsor-reported data. We will update this page if and when a peer-reviewed publication appears.

What the research actually says

Honest evidence summary

Citicoline has one of the cleanest mechanistic stories in cognitive science. The biochemistry — phosphatidylcholine synthesis via the Kennedy pathway, acetylcholine precursor delivery, and synaptic membrane formation — is textbook neurobiochemistry, not speculation. Few cognitive ingredients combine this level of mechanistic grounding with direct human biomarker evidence.

What studies consistently support

Citicoline’s biochemical mechanism is established at the textbook level: Kennedy pathway for phosphatidylcholine synthesis, acetylcholine precursor delivery, synaptic membrane formation.
Wurtman 2000 established oral bioavailability — ingested citicoline produces sustained increases in plasma choline and uridine (the precursors brain cells use).
Babb 2002 and Silveri 2008 demonstrated measurable brain biomarker changes (phospholipid metabolism, frontal-lobe ATP markers) after weeks of Cognizin® supplementation, using 4T MRS imaging.
McGlade 2012 reported attention measure associations at exactly the Xynaptic Drops™ serving size (250 mg) in healthy adult women — the dose-matched anchor study.
Nakazaki 2021 reported memory measure associations at 500 mg/day (matching Xynaptic™ at 2 mL cumulative) in adults 50–85 with age-associated memory changes.

What remains uncertain

No published head-to-head study has compared liposomal Cognizin® vs capsule Cognizin® in healthy adults. The liposomal format is positioned as a delivery alternative, not as a superior-bioavailability claim.
Whether the “14% brain energy” figure from Silveri 2008 transfers to the 250 mg serving. The study used 500–2,000 mg in n=16 open-label (no placebo). We do not transfer the quantitative figure.
Whether 250 mg/day produces memory effects at the McGlade-dose-matched serving. Memory associations were reported at 500 mg/day in Nakazaki 2021, not at 250 mg.
Whether the Nakazaki 2025 conference abstract findings will be confirmed in peer-reviewed publication — we’ll update when available.

What to realistically expect

At 1 mL (250 mg): attention support context per McGlade 2012, dose-matched.
At 2 mL cumulative (500 mg): memory and brain bioenergetics support context per Nakazaki 2021 and the Babb/Silveri imaging studies.
Effects build over weeks of consistent daily use. Attention associations were reported within 28 days (McGlade); memory associations at 12 weeks (Nakazaki); biomarker changes at 6 weeks (Babb).
The liposomal liquid format is designed for those who prefer liquid delivery or do not tolerate capsules — not for a bioavailability claim over capsule Cognizin®.

Professor 5-Brain — the honest take

Cognizin® is the most evidence-grounded ingredient in the entire Nutropx lineup — textbook biochemistry, human pharmacokinetics, brain imaging biomarker data, and dose-matched clinical trials at the serving size. That’s rare. What we won’t do: claim liposomal Cognizin is more bioavailable than capsule Cognizin (no head-to-head trial exists), claim 250 mg produces memory effects (memory data is at 500 mg), or use the “14% brain energy” figure as a product claim (that was 500–2,000 mg in an open-label study). We don’t need to overclaim. The honest story is already strong.

Why we selected this formulation

Formulation rationale

The form used in the published research. Every published clinical trial cited on this page used Cognizin® specifically, with the exception of the Wurtman 2000 pharmacokinetic study (which used generic CDP-choline to establish the mechanism). For an ingredient where formulation purity and stability matter for bioavailability, using the branded form studied in the trials is the most defensible product-formulation decision.

Liposomal delivery system. The Cognizin® in Xynaptic Drops™ is encapsulated within a sunflower-lecithin lipid bilayer — an established lipid-vesicle delivery technology. The liposomal format particularly serves those who do not tolerate capsules, have difficulty swallowing pills, or have compromised gut function. Note: citicoline is already well-absorbed orally per Wurtman 2000; no published head-to-head study has compared liposomal Cognizin® vs capsule Cognizin® bioavailability in healthy adults, so we position the liposomal format as a delivery alternative rather than as a superior-bioavailability claim.

The 250 mg dose-match advantage. Xynaptic Drops™’s 1 mL serving delivers 250 mg of Cognizin® — exactly the dose used in McGlade 2012, the published attention trial in healthy adult women. Few branded ingredients have a dose-matched published trial at their standard serving size. The 2 mL cumulative serving (500 mg) matches the dose used in Nakazaki 2021 (memory) and Silveri 2008 / Babb 2002 (brain imaging).

Regulatory standing. Cognizin® holds self-affirmed GRAS status (2009) for up to 250 mg/serving and is authorized by the European Commission as a Novel Food (Commission Implementing Decision 2014/423/EU, 2014) at up to 500 mg/day in supplements. The 250 mg per 1 mL serving of Xynaptic Drops™ sits at the exact upper limit of US self-affirmed GRAS and well within EU authorization.

Dosage & timing

Xynaptic Drops™ serving

250 mg

Cognizin® per 1 mL · 500 mg at 2 mL cumulative

1 mL (250 mg) matches the dose used in McGlade 2012 attention trial in healthy women; supported for daily attention/focus context

2 mL cumulative (500 mg) matches the dose used in Nakazaki 2021 memory trial and Babb 2002 / Silveri 2008 imaging studies; supported for memory and brain energy context in adults 50+

Take in the morning — citicoline supports attention and alertness; late-day use may affect sleep onset in some individuals

Shake well before each use; the liposomal liquid format relies on lipid-vesicle dispersion

Storage: store in a cool, dry place; best if used within 60 days of opening

Color, flavor, and sweetness may vary slightly between bottles due to natural variation in lemon oil and stevia

Effects on attention measures were observed within 28 days in McGlade 2012; memory and biomarker changes were observed at 6–12 weeks. Effects accumulate with consistent daily use.

Safety & tolerability

Established tolerability

Cognizin® has self-affirmed GRAS status (2009) for up to 250 mg/serving
EFSA Novel Food authorization (Commission Implementing Decision 2014/423/EU) for up to 500 mg/day in supplements
Citicoline has a long clinical history with rare and mild adverse effects
No serious adverse events reported in the published Cognizin-specific trials cited here
Most common mild effects: GI disturbance, transient headache, restlessness

Notes & cautions

Pregnancy and breastfeeding: insufficient data; consult your healthcare provider
Levodopa users: theoretical caution due to citicoline’s dopaminergic activity; consult provider
Antipsychotic medications: theoretical caution; consult provider
Not established for children — not recommended for pediatric use
Occasional reports of mild blood-pressure or heart-rate effects at higher doses
Discontinue at least 2 weeks before scheduled surgery as a precaution

Frequently asked questions

What does “liposomal” mean, and why use a liposomal format for citicoline?

Liposomes are microscopic spherical structures formed from phospholipid bilayers — the same class of lipid that makes up natural cell membranes. In Xynaptic Drops™, the Cognizin® citicoline is encapsulated within liposomes built from sunflower lecithin. Liposomal delivery is an established lipid-vesicle technology that mimics the lipid environment of cell membranes and offers an alternative to capsule or tablet formats. Honest framing: citicoline is already well-absorbed orally per Wurtman 2000 (oral CDP-choline produces sustained plasma choline and uridine increases), and no published head-to-head study has directly compared liposomal Cognizin® against capsule Cognizin® in healthy adults. We position the liposomal format as a delivery alternative — particularly useful for those who do not tolerate capsules, have difficulty swallowing pills, or prefer a liquid format — rather than as a superior-bioavailability claim over capsule Cognizin®.

What’s the difference between Cognizin® and generic citicoline?

Cognizin® is Kyowa Hakko Bio’s patented, branded form of citicoline (CDP-choline), trademarked in 2004. Every published clinical trial cited on this page used Cognizin® specifically, with the exception of the Wurtman 2000 pharmacokinetic study. Generic citicoline products may differ in purity, stability, and manufacturing standards. For an ingredient where formulation matters for bioavailability, using the branded form studied in the published trials is the most defensible product-formulation choice. Xynaptic Drops™ uses Cognizin® specifically.

Why is Xynaptic Drops™ a separate product from 5-Brain®?

Xynaptic Drops™ is a liposomal liquid citicoline format, while 5-Brain® is a multi-ingredient capsule formula covering six different cognitive mechanisms. They are designed for different use cases: Xynaptic for those who want focused citicoline support at the dose-matched 250 mg serving in a liquid liposomal format, and 5-Brain® for those who want broad multi-mechanism support. They can be used together, since citicoline’s phosphatidylcholine-synthesis mechanism is complementary to the mechanisms covered by 5-Brain®.

Why does the “14% brain energy” figure not appear as a product claim?

The 14% figure comes from Silveri et al. 2008, which measured frontal-lobe ATP-related compounds using 4-Tesla phosphorus MRS in n=16 healthy adults at 500 or 2000 mg/day of Cognizin® over 6 weeks. It is a real measurement from a real study. However: the study used 500 or 2000 mg/day (not the 250 mg per 1 mL Xynaptic serving), was open-label with no placebo arm, and had a small sample size. We do not transfer that specific quantitative figure to the 250 mg serving level. The underlying mechanism — that citicoline supports brain bioenergetics through phospholipid metabolism — is appropriately supported by the Silveri 2008 and Babb 2002 imaging studies as a mechanistic finding.

How long until I notice effects?

It depends on what is being measured. McGlade 2012 reported associations with attention measures within 28 days at the 250 mg dose. Babb 2002 measured brain phospholipid metabolism biomarker changes at 6 weeks at 500 mg. Nakazaki 2021 reported memory measure associations at 12 weeks at 500 mg. The biochemistry supports both acute effects (acetylcholine precursor delivery happens within hours of dosing per Wurtman 2000 pharmacokinetics) and cumulative effects (membrane phospholipid changes accumulate over weeks). Plan for at least 4 weeks of consistent daily use to reach the timepoint where research literature most consistently reports associations.

Can I take 1 mL or 2 mL? What’s the difference?

Both are supported by the published research, but at different effect contexts. 1 mL (250 mg) matches the dose used in McGlade 2012, where researchers reported associations with attention measures in healthy women. 2 mL cumulative (500 mg) matches the dose used in Nakazaki 2021 (memory in adults 50–85) and the Babb 2002 / Silveri 2008 imaging studies. The 500 mg upper level sits at the EFSA Novel Food authorized daily maximum. Choose based on your context: 1 mL for daily attention support, 2 mL for the higher-dose research context.

What’s in the bottle besides Cognizin®?

Per 1 mL serving: 250 mg Cognizin® Citicoline, 1 mg Stevia Leaf Extract (natural sweetener), and less than 1 g total carbohydrates. The other ingredients carry the liposomal delivery system and natural flavor: glycerin, water, oleic acid polyglyceride, lemon oil (natural flavor), sunflower lecithin (the lipid bilayer source), sunflower oil, xanthan gum (texture), potassium citrate, rosmarinic acid (natural preservative from rosemary), and natural mixed tocopherols (vitamin E forms, natural preservative). The product is Vegetarian, Gluten Free, and Soy Free. Color, flavor, and sweetness may vary slightly between bottles due to natural variation in the lemon oil and stevia.

← All Nutropx ingredient research

References
Babb SM et al. (2002) Psychopharmacology 161(3):248–54 · PMID 12021827 · Silveri MM et al. (2008) NMR Biomed 21(10):1066–75 · PMID 18816480 · McGlade E et al. (2012) Food Nutr Sci 3(6):769–73 · DOI 10.4236/fns.2012.36103 · McGlade E et al. (2019) J Atten Disord 23(2):121–34 · PMID 26179181 · Nakazaki E et al. (2021) J Nutr 151(8):2153–60 · PMID 33978188 · Wurtman RJ et al. (2000) Biochem Pharmacol 60(7):989–92 · PMID 10974208 · Świątkiewicz M, Grieb P (2023) Aging Dis 14(4):1184–95 · PMID 37196134 · Adibhatla RM, Hatcher JF, Dempsey RJ (2002) J Neurochem · DOI 10.1046/j.0022-3042.2001.00697.x (mechanism review) · EFSA NDA Panel (2013) EFSA Journal 11(10):3421 · EU Commission Decision 2014/423/EU

This page is for educational and informational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before beginning any supplement regimen, particularly if you are pregnant, nursing, taking medications (including levodopa, antipsychotics, or other prescription medications), or have a medical condition. Not recommended for children. Discontinue use at least 2 weeks before surgery. Cognizin® is a registered trademark of Kyowa Hakko Bio Co., Ltd.